

| SOURCE   | LINK  |
|--|---|
| Vredenburgh, J.J., et al., <i>Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and Irinotecan for treatment of malignant gliomas</i> , American Society of Clinical Oncology 42d Annual Meeting ,2006, Abstract 2003.                          | <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=47&amp;abstractID=33955">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=47&amp;abstractID=33955</a> |
| Stark-Vance, V., <i>Bevacizumab And CPT-11 in the Treatment of Relapsed Malignant Glioma</i> , Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and Sixth Meeting of the European Association for Neuro-Oncology, May 5-8, 2005, Abstract 342. | <a href="http://www.eano.eu/documents/pastcongresses/EANO2005_Conference_Abstacts.pdf">http://www.eano.eu/documents/pastcongresses/EANO2005_Conference_Abstacts.pdf</a>   |
| <i>FDA Approval of Colorectal Cancer Treatment – First to be Based on Survival Data</i> , Medicine on Line, Oct. 22, 1998.   | <a href="http://www.meds.com/colon/camptosar/release.html">http://www.meds.com/colon/camptosar/release.html</a>   |
| <i>Irinotecan</i> , Clinical Pharmacology Online.  | <a href="http://www.cponline.gsm.com">http://www.cponline.gsm.com</a>   |
| Hare, C.B., et al., <i>Therapeutic Efficacy of the Topoisomerase I Inhibitor 7-ethyl-10 (4-[1-piperdino]-1-piercino) Carbonyloxy-Camptothecin Against Pediatric and Adult Central Nervous System Tumor Xenographs</i> , Cancer Chemother Pharmacol 1997 39 (3) 187-91.         | Abstract at:<br><a href="http://www.springerlink.com/content/cfcmphh1q6mp8n7c/">http://www.springerlink.com/content/cfcmphh1q6mp8n7c/</a>   |
| Cottu P.H., Extra J.M., Lerebours F., Espie M., Marty M, <i>Clinical activity spectrum or Irinotecan</i> , Bull Cancer 1998 Dec. Spec No:21-5.   | Abstract at:<br><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9932080&amp;dopt=AbstractPlus">http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9932080&amp;dopt=AbstractPlus</a>   |
| Shimizu Y., Umezawa S., Hasumi K., <i>A phase II Study of Combined CPT-11 and Mitomycin-C in Plainum Refractory Clear Cell and Mucinous Ovarian Carcinoma</i> , Ann Acad Med Singapore 1988 Sep. 27(5):650-6.  | Abstract at:<br><a href="http://grande.nal.usda.gov/ibids/index.php?mode2=detail&amp;origin=ibids_references&amp;therow=359278">http://grande.nal.usda.gov/ibids/index.php?mode2=detail&amp;origin=ibids_references&amp;therow=359278</a>   |
| Rosen, L.S., <i>Irinotecan in Lymphoma,Leukemia, and Breast, Pancreatic, Ovarian, and Small-Cell Cancers</i> , Oncology (Hunting) 1988 Aug. 12(8 Suppl 6): 103-9.  | Abstract at:<br><a href="http://grande.nal.usda.gov/ibids/index.php?mode2=detail&amp;origin=ibids_references&amp;therow=361507">http://grande.nal.usda.gov/ibids/index.php?mode2=detail&amp;origin=ibids_references&amp;therow=361507</a>   |
| Jory, V, <i>CPT-11 For Brain Tumors</i> , Clinical Trials and Noteworthy Treatments for Brain Tumors (last updated May 2, 1999).   | <a href="http://www.virtualtrials.com/cpt11.cfm">http://www.virtualtrials.com/cpt11.cfm</a>   |
| Vredenburgh, J.J., et al., <i>Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma</i> , Clin Cancer Res 2007 Feb. 13(4): 1253-1259.   | Abstract at:<br><a href="http://clincancerres.aacrjournals.org/cgi/content/abstract/13/4/1253">http://clincancerres.aacrjournals.org/cgi/content/abstract/13/4/1253</a>   |
| Gonzalez, J., et. al., <i>Effect of bevacizumab on</i>   | Abstract at:  |

|  |  |
|--|--|
| <p><i>radiation necrosis of the brain</i>, Int J Radiat Oncol Biol Phys, 2007 Feb. 1, 67 (2):323-6.</p>  | <p><a href="http://cat.inist.fr/?aModele=afficheN&amp;cpsid=18476221">http://cat.inist.fr/?aModele=afficheN&amp;cpsid=18476221</a></p>   |
| <p>Pope, W.B., et al, <i>MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy</i>, Neurology 2006 Apr., 66: 1258–1260.</p>  | <p>Abstract at:<br/><a href="http://www.neurology.org/cgi/content/abstract/66/8/1258">http://www.neurology.org/cgi/content/abstract/66/8/1258</a></p>  |
| <p>Chamberlaine, M.C., et al, <i>MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy</i>, Neurology, Dec. 12, 2006; 67(11): 2089.</p>  | <p><b>[[Not bound into the appeal; there is a note appended to the Weaver letter noting that we were unable to find a copy of this study.]]</b><br/>Abstract at:<br/><a href="http://www.neurology.org/cgi/content/citation/67/11/2089">http://www.neurology.org/cgi/content/citation/67/11/2089</a></p>   |
| <p>Cloughesy, et. al, <i>Two Studies Evaluating Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen</i>, Cancer 2003 May, 97(9): 2381-2386.</p>                                  | <p>Abstract at:<br/><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;uid=12712460&amp;cmd=showdetailview&amp;indexed=google">http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;uid=12712460&amp;cmd=showdetailview&amp;indexed=google</a></p>  |
| <p>Friedman, et. al., <i>Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma</i>, Jour Clin Onc 1999 May; 17(5):1516-1525.</p>   | <p>Abstract at:<br/><a href="http://jco.ascopubs.org/cgi/content/abstract/17/5/1516">http://jco.ascopubs.org/cgi/content/abstract/17/5/1516</a></p>  |
| <p>Raval, S., et al, <i>Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (gbm)</i>, Jour Clin Onc 2007 (June 20 Supplement); 25(18S): 2078.</p>                             | <p><a href="http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2078">http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2078</a></p>   |
| <p>Friedland, D.M., et al, <i>Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case series</i>, Jour Clin Onc 2007 (June 20 Supplement); 25(18S): 12500.</p>           | <p><a href="http://meeting.jco.org/cgi/content/abstract/25/18_suppl/12500">http://meeting.jco.org/cgi/content/abstract/25/18_suppl/12500</a></p>   |
| <p>Kang, T., et al, <i>Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience</i>, American Society of Clinical Oncology 43d Annual Meeting, 2007, Abstract 2077.</p> | <p><a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=47&amp;abstractID=31076">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=47&amp;abstractID=31076</a></p> |
| <p>Jory, V, <i>CPT-11 For Brain Tumors</i>, Clinical Trials and Noteworthy Treatments for Brain Tumors (last updated May 2, 1999).</p>   | <p><a href="http://www.virtualtrials.com/cpt11.cfm">http://www.virtualtrials.com/cpt11.cfm</a></p>   |